Delta-like 4/Notch signaling and its therapeutic implications - PubMed (original) (raw)
Review
Delta-like 4/Notch signaling and its therapeutic implications
Minhong Yan et al. Clin Cancer Res. 2007.
Abstract
Intense research efforts have been focused toward the identification of regulators of angiogenesis and the development of antiangiogenesis-based cancer therapies. The approval of anti-vascular endothelial growth factor (VEGF) monoclonal antibody (bevacizumab) for use in colorectal and lung cancer provides clinical validation for targeting angiogenesis for the treatment of cancer. Delta-like 4 (Dll4)-mediated Notch signaling represents another key pathway essential for vascular development. Recent studies yield substantial insights into the role of Dll4 in angiogenesis. Dll4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of Dll4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. In preclinical studies, blocking of Dll4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Dll4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy, especially when resistance to and/or escape from existing therapies evolve.
Similar articles
- Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. Noguera-Troise I, et al. Nature. 2006 Dec 21;444(7122):1032-7. doi: 10.1038/nature05355. Nature. 2006. PMID: 17183313 - DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, Harris AL. Li JL, et al. Cancer Res. 2011 Sep 15;71(18):6073-83. doi: 10.1158/0008-5472.CAN-11-1704. Epub 2011 Jul 29. Cancer Res. 2011. PMID: 21803743 - Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL. Li JL, et al. Cancer Res. 2007 Dec 1;67(23):11244-53. doi: 10.1158/0008-5472.CAN-07-0969. Cancer Res. 2007. PMID: 18056450 - Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?
Sainson RC, Harris AL. Sainson RC, et al. Trends Mol Med. 2007 Sep;13(9):389-95. doi: 10.1016/j.molmed.2007.07.002. Epub 2007 Sep 6. Trends Mol Med. 2007. PMID: 17822956 Review. - Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ, Ellis LM. Hicklin DJ, et al. J Clin Oncol. 2005 Feb 10;23(5):1011-27. doi: 10.1200/JCO.2005.06.081. Epub 2004 Dec 7. J Clin Oncol. 2005. PMID: 15585754 Review.
Cited by
- The involvement of Notch signaling in melanoma vasculogenic mimicry.
Vartanian A, Gatsina G, Grigorieva I, Solomko E, Dombrovsky V, Baryshnikov A, Stepanova E. Vartanian A, et al. Clin Exp Med. 2013 Aug;13(3):201-9. doi: 10.1007/s10238-012-0190-9. Epub 2012 May 25. Clin Exp Med. 2013. PMID: 22627943 - Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells.
Morrow DJ, Avissar NE, Toia L, Redmond EM, Watson TJ, Jones C, Raymond DP, Litle V, Peters JH. Morrow DJ, et al. Surgery. 2009 Oct;146(4):714-21; discussion 721-2. doi: 10.1016/j.surg.2009.06.050. Surgery. 2009. PMID: 19789031 Free PMC article. - New developments in the treatment of ovarian cancer--future perspectives.
Lopez J, Banerjee S, Kaye SB. Lopez J, et al. Ann Oncol. 2013 Dec;24 Suppl 10(Suppl 10):x69-x76. doi: 10.1093/annonc/mdt475. Ann Oncol. 2013. PMID: 24265409 Free PMC article. Review. - Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.
Choi Y, Jung K. Choi Y, et al. Exp Mol Med. 2023 Nov;55(11):2308-2319. doi: 10.1038/s12276-023-01114-w. Epub 2023 Nov 1. Exp Mol Med. 2023. PMID: 37907742 Free PMC article. Review. - Biology and therapeutic targeting of vascular endothelial growth factor A.
Pérez-Gutiérrez L, Ferrara N. Pérez-Gutiérrez L, et al. Nat Rev Mol Cell Biol. 2023 Nov;24(11):816-834. doi: 10.1038/s41580-023-00631-w. Epub 2023 Jul 25. Nat Rev Mol Cell Biol. 2023. PMID: 37491579 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources